SLC5A2 and Cirrhosis: A large systematic review involving over one million patients reported that, compared to other glucose-lowering agents, SGLT2 inhibitors were associated with the most significant reductions in MASLD incidence, progression to cirrhosis, and composite liver-related events [23].